Abstract: A method of making a cell sheet comprising secondary spheroids, including (a) obtaining cardiosphere-derived cells; (b) cultivating the cardiosphere-derived cells for a first period of time in a first media comprising at least one of an ascorbic acid and an analog thereof, to form secondary spheroids; (c) transferring an amount of the spheroids formed in step (b) into a mold; (d) culturing the secondary spheroids for a second period of time in a second media comprising at least one of the ascorbic acid and an analog thereof, wherein the at least one of the ascorbic acid and an analog thereof is present in an amount effective to promote a formation of an extracellular matrix; and (e) culturing a product obtained in step (d) for a third period of time, in the absence of the at least one of the ascorbic acid and an analog thereof.
Abstract: The present disclosure provides methods to improve the viability of an organ, or organs, by continuously administering a composition comprising NOx gas directly to the organ(s).
Abstract: Disclosed are compositions, in particular, organoid compositions, derived from more than one donor cell. Further disclosed are methods of making compositions, for example, organoid compositions, that comprise a differentiated cell population derived from more than one donor cell. Donor cells may include, for example, a precursor cell such as an embryonic stem cell or other precursor cell. The disclosed methods use synchronization conditions to produce a synchronized pooled-precursor cell population, which may then be differentiated into an organoid composition. Methods of using the compositions are also disclosed.
Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
Type:
Grant
Filed:
December 11, 2023
Date of Patent:
April 15, 2025
Assignee:
United Therapeutics Corporation
Inventors:
Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
Abstract: A method and apparatus of aseptic processing and production of cells in a non-sterile enclosure apparatus without chemical biocides is disclosed, by controlling the level of humidity throughout the enclosure to 25% relative humidity (RH) or less, and preferably 20% or 15% or less RH. In addition, the temperature is controlled to 37° C., and consistent gas flow is maintained the enclosure. Colony forming units from microbial contamination detected by environmental monitoring within the enclosure are significantly reduced in this method.
Abstract: A method of remediation of soil and groundwater containing hydrocarbons and halogenated compounds. The method includes introducing a remediation composition into the soil that includes: (a) a first bioremediation material including a first blend of organisms capable of degrading the hydrocarbons; (b) a second bioremediation material including a second blend of organisms differing from the first blend of organisms that is chosen for degrading the halogenated compounds; (c) an organic compound such as a complex carbohydrate (e.g., food grade starch); and (d) a third blend of organisms degrading the organic compound. The degrading of the organic compound breaks the complex carbohydrate into smaller molecules that are utilized by the microorganisms of at least one of the first and second bioremediation materials during the degrading of the hydrocarbons and the halogenated compounds.
Abstract: The invention provides method for preparing amnion tissue grafts, as well as the grafts themselves. In specific embodiments, the tissue graft comprises a single layer of dried amnion from an umbilical cord.
Abstract: The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.
Type:
Grant
Filed:
September 24, 2021
Date of Patent:
April 1, 2025
Assignee:
FOLLICA, INC.
Inventors:
Shikha P. Barman, William D. Ju, Scott C. Kellogg, Stephen M. Prouty, Eric Schweiger, Seth Lederman, Mary Osbakken, Alan D. Schinazi
Abstract: The present invention provides methods, agents, compounds, and compositions useful for administering to subjects having or at risk of having anemias. In certain embodiments, methods herein comprise administering two agents to a subject, which are useful for the treatment of an anemia.
Abstract: Methods and techniques for controlled printing of a cell sample for karyotyping are provided. The methods can involve matrix printing using on-the-fly printing or dispensing to accurately spread cells within at least one cell sample on a surface in preparation for karyotyping, and further analysis. Advantageously, the methods result in a uniform distribution of chromosomes of the cell suspension or sample on the surface of a substrate which can be substantially discretely identified, and also provide for efficiency in a subsequent staining process and any further analysis of the stained chromosomes using a microscope or other imaging device.
Type:
Grant
Filed:
November 22, 2021
Date of Patent:
March 25, 2025
Assignee:
Biodot, Inc.
Inventors:
Brian L. Kirk, Anthony V. Lemmo, Thomas C. Tisone
Abstract: Provided are defined culture media for culturing pluripotent stem cells in a suspension culture devoid of substrate adherence, the defined culture media comprising an effective amount of a protease inhibitor; a GSK3? inhibitor and at least one agent selected from the group consisting of a protease inhibitor and a WNT3A polypeptide; a WNT3A polypeptide and a stabilizing agent thereof with the proviso that said stabilizing agent is not a lipid vesicle; and/or a GSK3? inhibitor, with the proviso that the medium is devoid of an ERK1/2 inhibitor. Also provided are cell cultures and methods of suing same.
Abstract: Provided herein are compositions and methods for the cryopreservation of immune cells, such as peripheral blood mononuclear cells (PBMCs) by pre-treating the cells with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein) prior to freezing. Kits for practicing the methods are also provided herein.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
March 18, 2025
Assignee:
HTYR Acquisition LLC
Inventors:
Yosef Refaeli, Brian C. Turner, Thomas R. Payne
Abstract: Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.
Type:
Grant
Filed:
September 6, 2023
Date of Patent:
March 11, 2025
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Donald E. Ingber, Magdalena Kasendra, Alexandra Sontheimer-Phelps, Alessio Tovaglieri
Abstract: The present invention concerns the therapeutic use of extracellular vesicles isolated from a genetically modified cell line over-expressing SerpinB3. In particular, said therapeutic use aimed at the treatment of acute pathologies characterized by ischemic or inflammatory tissue damage or by cell injury due to oxidative stress, such as cardiac, cerebral, intestinal, renal or limb ischaemia. Further examples of use consist of the preservation of transplant organs, including heart, lung, liver, bladder, pancreas and intestine. In a further aspect the invention relates to the use of a pharmaceutical composition comprising extracellular vesicles isolated from a genetically modified cell line over-expressing SerpinB3 and a pharmaceutically acceptable vehicle.
Abstract: A pH-modulating poly(glycerol sebacate) composition includes poly(glycerol sebacate) and at least one pH-modulating agent associated with the poly(glycerol sebacate). A process of making a pH-modulating poly(glycerol sebacate) composition includes forming a poly(glycerol sebacate) by a water-mediated reaction from glycerol and sebacic acid and associating at least one pH-modulating agent with the poly(glycerol sebacate). A process of modulating a pH of a buffered aqueous solution includes placing a pH-modulating poly(glycerol sebacate) composition in a buffered aqueous solution. The pH-modulating agent is released into the buffered aqueous solution during degradation of the poly(glycerol sebacate) to reduce a decrease in pH of the buffered aqueous solution caused by degradation of the poly(glycerol sebacate).
Type:
Grant
Filed:
August 18, 2021
Date of Patent:
February 11, 2025
Assignee:
THE SECANT GROUP, LLC
Inventors:
Peter D. Gabriele, Jeremy J. Harris, Charles Brendan Nicholson, Steven Lu, Brian Ginn
Abstract: Disclosed are compositions comprising a MSC secretome preparation and cannabinoids and methods of the use of said compositions for the treatment of inflammatory conditions.
Type:
Grant
Filed:
July 20, 2020
Date of Patent:
February 4, 2025
Assignee:
DIRECT BIOLOGICS, LLC
Inventors:
Kenneth Allen Pettine, Timothy Alexander Moseley
Abstract: Disclosed are methods for treating platelet compositions (e.g. platelet concentrates and/or platelet lysates) with electron beam radiation, where the compositions are in a frozen state during irradiation with the e-beam radiation. The methods can be conducted using e-beam radiation at doses effective to reduce the pathogen content of the compositions while retaining highly beneficial bioactivities of the compositions. Also disclosed are compositions preparable by the methods, and methods and compositions involving the use of the e-beam treated materials.
Abstract: A method for fixing a biological sample includes delivering energy through a biological sample that has been removed from a subject, while fixing the biological sample. A change in speed of the energy traveling through the biological sample is evaluated to monitor the progress of the fixation. A system for performing the method can include a transmitter that outputs the energy and a receiver configured to detect the transmitted energy. A computing device can evaluate the speed of the energy based on signals from the receiver.
Type:
Grant
Filed:
February 9, 2023
Date of Patent:
February 4, 2025
Assignee:
Ventana Medical Systems, Inc.
Inventors:
David Chafin, Michael Otter, Abbey Pierson, Jefferson Curtis Taft
Abstract: A method for mosquito control is provided in the form of mosquito larvicide carrying insects which can be introduced in a mosquito population to thereby control the mosquito population. The larvicide carrier insects may include artificially generated adult insect carriers of a mosquito larvicide in which the mosquito larvicide has minimal impact on the adult insect carrier and which mosquito larvicide affects juvenile mosquito survival or interferes with metamorphosis of juvenile mosquitoes to adulthood. The larvicide carrier insects may be either male or female and may include mosquitoes and non-mosquito insects.